株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

緑膿菌性肺炎:パイプライン製品の分析

Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2018

発行 Global Markets Direct 商品コード 484628
出版日 ページ情報 英文 33 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.52円で換算しております。
Back to Top
緑膿菌性肺炎:パイプライン製品の分析 Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2018
出版日: 2018年09月26日 ページ情報: 英文 33 Pages
概要

緑膿菌は、肺炎の重要な原因で、1週間以上入院した患者から取り出される最も一般的病原体です。症候は、熱、疲労、かゆい発疹、出血性潰瘍と頭痛などがあります。危険因子は、年齢と免疫力の低下などが挙げられます。治療には抗生物質を使います。

当レポートでは、世界各国での緑膿菌性肺炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

緑膿菌性肺炎;概要

緑膿菌性肺炎 - 治療薬の開発

  • パイプライン製品 概要
  • パイプライン製品:企業別
  • パイプライン製品:大学/研究機関別
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Aridis Pharmaceuticals LLC
  • Emergent BioSolutions Inc
  • MedImmune LLC
  • Polyphor Ltd

薬剤プロファイル

休止中のプロジェクト

付録

図表

図表

List of Tables

  • Number of Products under Development for Pseudomonas aeruginosa Pneumonia, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pseudomonas aeruginosa Pneumonia - Pipeline by Aridis Pharmaceuticals Inc, H2 2018
  • Pseudomonas aeruginosa Pneumonia - Pipeline by MedImmune LLC, H2 2018
  • Pseudomonas aeruginosa Pneumonia - Pipeline by Polyphor AG, H2 2018
  • Pseudomonas aeruginosa Pneumonia - Dormant Projects, H2 2018

List of Figures

  • Number of Products under Development for Pseudomonas aeruginosa Pneumonia, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products by Targets, H2 2018
  • Number of Products by Stage and Targets, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
目次
Product Code: GMDHC10788IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2018, provides an overview of the Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline landscape.

Pseudomonas aeruginosa has become an important cause of pneumonia. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pseudomonas aeruginosa Pneumonia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Pneumonia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pseudomonas aeruginosa Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pseudomonas aeruginosa Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pseudomonas aeruginosa Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Pneumonia (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pseudomonas aeruginosa Pneumonia - Overview
    • Pseudomonas aeruginosa Pneumonia - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Pseudomonas aeruginosa Pneumonia - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pseudomonas aeruginosa Pneumonia - Companies Involved in Therapeutics Development
    • Aridis Pharmaceuticals Inc
    • MedImmune LLC
    • Polyphor AG
  • Pseudomonas aeruginosa Pneumonia - Drug Profiles
    • Aerucin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Pseudomonas aeruginosa Pneumonia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-3902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • panobacumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • POL-7001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzyme for Pseudomonas Aeruginosa Pneumonia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pseudomonas aeruginosa Pneumonia - Dormant Projects
  • Pseudomonas aeruginosa Pneumonia - Product Development Milestones
    • Featured News & Press Releases
      • Sep 26, 2017: Study Investigates Novel Immunotherapeutic Delivery Strategy for Preventing Infection with Antibiotic Resistant Bacteria
      • Aug 02, 2017: Aridis Pharmaceuticals Enrolls First Patients in Global Pivotal Clinical Trial of Novel Monoclonal Antibody for Treating Acute Pneumonia
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top